Core Viewpoint - ImmunityBio, Inc. is facing a securities class action lawsuit following a warning from the FDA regarding misleading claims about its cancer treatment product, Anktiva, which has resulted in a significant drop in the company's market capitalization by nearly $2 billion [1][7]. Group 1: Lawsuit and FDA Warning - The class action lawsuit seeks to represent investors who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026 [1]. - The FDA issued a warning letter to ImmunityBio concerning claims made by its executive chairman, Dr. Patrick Soon-Shiong, about Anktiva's efficacy, which the FDA deemed misleading [2][7]. - Following the FDA's warning, ImmunityBio's share price fell over 21% on March 24, 2026, leading to a loss of nearly $2 billion in market capitalization [2][7]. Group 2: Company Background and Product Information - ImmunityBio is a biotechnology company focused on developing immunotherapies aimed at activating the immune system to combat cancer and infectious diseases [4]. - Anktiva is an FDA-approved immunotherapy used in conjunction with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) [5]. - The lawsuit centers on the legitimacy of ImmunityBio's claims regarding Anktiva's effectiveness in treating other types of cancer beyond its approved indication [5][6]. Group 3: Investigation and Implications - Hagens Berman, a national shareholders rights firm, is investigating claims that ImmunityBio violated federal securities laws by misleading investors about Anktiva's efficacy [3][8]. - The FDA's warning highlighted that promotional materials created a misleading impression that Anktiva could cure and prevent all cancers, which has not been substantiated by data [7]. - The firm is encouraging investors who suffered losses to come forward and is also seeking witnesses to assist in the investigation [3][8].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Earlier this month, Relmada Therapeutics, Inc. ( RLMD ) stock surged in value from ~$4.5 to >$7, up ~55%. The gains were triggered by the Coral Gables, Florida-based biotech's reporting Phase 2 clinical study data ...

Core Viewpoint - A class action has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product Anktiva, particularly regarding its capabilities in treating cancer [1][2]. Allegations - The complaint claims that Soon-Shiong, a defendant in the case, materially overstated Anktiva's capabilities during the class period [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancer [3]. Stock Impact - Following the FDA warning letter, ImmunityBio's stock price fell by $1.98 per share, or 21%, closing at $7.42 per share on March 24, 2026 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 26, 2026, and can remain absent class members if they choose not to participate [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. What It Means for the Stock. By Mackenzie Tatananni Share Resize Reprints In this article SPX DJIA PFE Eli Lilly Deal Is a Bet on AI. What It Means for the Stock. - Barron's Skip to Main Content This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0 ...

Group 1: Longlaville Plant Project - Carbios confirms its objective to build the Longlaville plant and is working on structuring the necessary financing to resume the project [2] - The estimated construction cost of the plant is €230 million, with €42.5 million in public funding already secured [3][2] - Stakeholders aim to finalize the financing components in the coming weeks, targeting a deal closure by Q3 2026 [3] Group 2: Governance Update - Carbios has appointed Benoît Grenot as Deputy Chief Executive Officer to support the execution of development projects, including the Longlaville project [6] - The leadership believes Grenot's international experience and operational discipline will be crucial for finalizing financing and ensuring the success of strategic partnerships [7] Group 3: Financial Situation - Carbios has a solid cash position of approximately €60 million as of December 2025, allowing it to cover operating expenses for over the next 12 months [11][8] - Projected cash consumption for 2026, excluding the Longlaville project, is estimated at around €20 million [11] Group 4: Legal Proceedings Update - Two legal actions have been initiated against Carbios following the departure of a former executive, with the company planning to defend itself vigorously [12] - Carbios has filed a complaint for false accusation and a motion for retraction regarding seized documents [13] Group 5: Industry Context - The French and European regulatory frameworks increasingly support chemical recycling, which bolsters Carbios' confidence in securing pre-sales contracts for products from the Longlaville plant [4] - The IMPR decree in France and the SUPD implementing decision at the European level recognize chemical recycling and provide incentives for incorporating recycled plastics [22]

Group 1: Company Performance - Moderna reported full-year 2025 revenue of $1.944 billion, a decrease of 39.23% year over year, with a net loss of $2.822 billion and negative free cash flow of $2.065 billion [2] - BioNTech achieved full-year 2025 revenue growth of 4.3% to €2.87 billion (approximately $3.25 billion), with €17.2 billion (approximately $19.4 billion) in cash and positive operating cash flow of €403 million (approximately $456 million) [5][11] - Novavax posted profitable results with an EPS of $0.11, significantly beating estimates of negative $0.42, and revenue rose 66.6% year over year to $147.14 million, largely due to a partnership with Sanofi [7][5] Group 2: Market Position and Analyst Sentiment - Moderna is currently trading 13.6% above the Wall Street consensus target of $43.75, despite its financial struggles [5] - BioNTech has strong analyst conviction with 14 Buys and a consensus target of $130.72, implying a 52.4% upside from the current price of $85.86 [12] - Novavax's stock is highly volatile with a beta of 2.63, and while it is currently profitable, its path to sustainable growth remains uncertain [9] Group 3: Future Prospects and Challenges - BioNTech's oncology pipeline includes multiple Phase 3 trials planned in partnership with Bristol Myers Squibb, indicating a robust future growth strategy [12] - Moderna's financials suggest a need for a recovery that has not yet materialized, raising concerns about its sustainability [6] - Novavax's reliance on partnerships for survival and negative shareholder equity present significant risks, despite its current profitability [9]

Core Insights - United Therapeutics announced positive Phase 3 study results for nebulized Tyvaso, showing a reduction in clinical worsening of idiopathic pulmonary fibrosis (IPF) compared to a placebo, leading to a significant increase in stock price [1][6]. Company Developments - The company plans to seek priority review from the FDA to add IPF to the labeled indications for nebulized Tyvaso by the end of summer, based on results from the TETON-1 and TETON-2 studies, with no new safety concerns reported [2]. - Tyvaso is currently approved for treating pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease, and its potential approval for IPF could add an estimated $5.4 billion to United's revenue by 2033 [4]. Market Performance - United Therapeutics stock surged 17.6% to $615.00 in early trading, following the announcement, and previously closed at $522.83, just above a buy point of $519.99 [6]. - The stock's relative strength line is reaching new highs, and it holds a 98 IBD Composite Rating, ranking second in its industry group [7].

Core Insights - Q32 Bio Inc. is a clinical-stage biotech company focused on developing Bempikibart, a treatment candidate for alopecia areata (AA) [1] - Bempikibart is currently in Phase 2a of the SIGNAL-AA trial and has shown positive data from previous studies [1] Company Overview - Q32 Bio Inc. specializes in biotechnology with a focus on innovative treatments for dermatological conditions [1] - The company is advancing its lead candidate, Bempikibart, through clinical trials to address unmet medical needs in alopecia areata [1]

Core Insights - Quince Therapeutics, Inc. has successfully settled its outstanding obligations under a loan from the European Investment Bank for a payment of $5.5 million, marking a significant milestone for the company [1] Financial Summary - The settlement of the $5.5 million loan resolves critical debt obligations for Quince Therapeutics, enabling the company to advance its restructuring efforts [1] - This financial move is aimed at evaluating strategic alternatives to maximize shareholder value [1]